FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an isolated antibody that specifically binds human CD73 on the cell surface and is able to neutralize its 5' - ectonucleotidase activity. A pharmaceutical composition for cancer treatment containing the above antibody is also disclosed. The invention also relates to a recombinant host cell producing the above antibody.
EFFECT: invention makes it possible to effectively treat cancer.
20 cl, 2 tbl, 9 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CD73 BLOCKING ANTIBODIES | 2020 |
|
RU2819204C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| METHODS AND COMPOSITIONS BASED ON ANTI-CD73 ANTIBODIES AND VERSIONS THEREOF | 2020 |
|
RU2841372C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| MULTISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION AND USE THEREOF | 2018 |
|
RU2837770C2 |
